rosiglitazone has been researched along with Experimental Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q; Rao, J; Yang, C; Yang, H; Zhang, W; Zhang, X | 1 |
| Cao, J; Feng, Y; Gao, Y; Li, X; Qian, K; Shen, W; Wang, G; Wang, Z; Xu, X; Yue, L; Zhang, S | 1 |
| Chen, C; Huang, G; Lan, J; Li, M; Lu, Y; Mo, X; Na, F; Tong, R; Xue, J; Yin, L | 1 |
3 other study(ies) available for rosiglitazone and Experimental Neoplasms
| Article | Year |
|---|---|
Curcumin exerts anti-tumor effects on diffuse large B cell lymphoma via regulating PPARγ expression.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Curcumin; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice, SCID; Neoplasms, Experimental; PPAR gamma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells.
Topics: Animals; Cell Survival; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; PPAR gamma; Rosiglitazone; Tumor Cells, Cultured; X-Rays | 2020 |
Synergy between peroxisome proliferator-activated receptor γ agonist and radiotherapy in cancer.
Topics: Animals; Chemoradiotherapy; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Microenvironment | 2018 |